Medicine compound against acute myeloid leukemia

Abstract

The invention discloses a medicine compound against acute myeloid leukemia; each unit dose of the medicine compound contains 2mg of all-trans-retinoic acid, 1 to 2mg of megestrol acetate, 100 to 200mg of bezafibrate and a carrier acceptable of medical science, and the mass ratio of megestrol acetate to bezafibrate is 1:100. The medicine compound can significantly improve the survival rate of patients with acute myeloid leukemia, and can open up a new way for clinical treatment.

Description

technical field

[0001] The invention relates to an anti-acute myeloid leukemia pharmaceutical composition, in particular to an anti-acute myeloid leukemia pharmaceutical composition containing bezafibrate and megestrol. Background technique

[0002] The incidence rate of leukemia in my country is 2.76 / 10 5 , among which the annual incidence rate of acute myeloid leukemia (AML) is the highest, reaching 1.62 / 10 5 . AML is a serious type of leukemia, which is mainly caused by the excessive proliferation of abnormal hematopoietic cells caused by the abnormal clone of myeloid hematopoietic stem cells, the inhibition of differentiation and the inhibition of apoptosis. Its incidence rate increases with age, and the median age is 65 to 70 years old. Clinically, the treatment of acute myeloid leukemia is more difficult, on the one hand because of its rapid onset, on the other hand because the vast majority of patients are elderly with weak physical functions and often cannot toler...

Images